Cargando…

Cerebrospinal Fluid and Blood Biomarkers of Neuroaxonal Damage in Multiple Sclerosis

Following emerging evidence that neurodegenerative processes in multiple sclerosis (MS) are present from its early stages, an intensive scientific interest has been directed to biomarkers of neuro-axonal damage in body fluids of MS patients. Recent research has introduced new candidate biomarkers bu...

Descripción completa

Detalles Bibliográficos
Autor principal:	Dujmovic, Irena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198600/ https://www.ncbi.nlm.nih.gov/pubmed/22096642 http://dx.doi.org/10.1155/2011/767083

Ejemplares similares

Neuronal and Neuroaxonal Damage Cerebrospinal Fluid Biomarkers in Autoimmune Encephalitis Associated or Not with the Presence of Tumor
por: Vakrakou, Aigli G., et al.
Publicado: (2022)

Blood and Cerebrospinal Fluid α‐Tocopherol and Selenium Concentrations in Neonatal Foals with Neuroaxonal Dystrophy
por: Finno, C.J., et al.
Publicado: (2015)

Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients
por: Moser, Tobias, et al.
Publicado: (2021)

Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort
por: Oertel, Frederike Cosima, et al.
Publicado: (2023)

Multiple Sclerosis Cerebrospinal Fluid Biomarkers
por: Giovannoni, Gavin
Publicado: (2006)

Cerebrospinal fluid in COVID-19 neurological complications: Neuroaxonal damage, anti-SARS-Cov2 antibodies but no evidence of cytokine storm
por: Garcia, Maria A., et al.
Publicado: (2021)

Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis
por: Loonstra, Floor C., et al.
Publicado: (2022)

Cerebrospinal fluid in multiple sclerosis
por: Rammohan, Kottil W.
Publicado: (2009)

Diabetes and Neuroaxonal Damage in Parkinson's Disease
por: Vijiaratnam, Nirosen, et al.
Publicado: (2022)

MicroRNAs in blood and cerebrospinal fluid as diagnostic biomarkers of multiple sclerosis and to monitor disease progression
por: Martinez, Bridget, et al.
Publicado: (2019)

Are Cerebrospinal Fluid Biomarkers Useful in Predicting the Prognosis of Multiple Sclerosis Patients?
por: Gajofatto, Alberto, et al.
Publicado: (2011)

Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers
por: Gaetani, Lorenzo, et al.
Publicado: (2020)

The Cerebrospinal Fluid in Multiple Sclerosis
por: Deisenhammer, Florian, et al.
Publicado: (2019)

Serum and Cerebrospinal Fluid Cytokine Biomarkers for Diagnosis of Multiple Sclerosis
por: Martynova, Ekaterina, et al.
Publicado: (2020)

Evolution of Cortical and White Matter Lesion Load in Early-Stage Multiple Sclerosis: Correlation With Neuroaxonal Damage and Clinical Changes
por: Todea, Ramona-Alexandra, et al.
Publicado: (2020)

Cerebrospinal Fluid Analysis in Multiple Sclerosis Diagnosis: An Update
por: Lo Sasso, Bruna, et al.
Publicado: (2019)

The cerebrospinal fluid in multiple sclerosis: far beyond the bands
por: Domingues, Renan Barros, et al.
Publicado: (2017)

Diagnostic Cerebrospinal Fluid Biomarker in Early and Late Onset Multiple Sclerosis
por: Konen, Franz Felix, et al.
Publicado: (2022)

Cerebrospinal fluid and serum proteomic profiles accurately distinguish neuroaxonal dystrophy from cervical vertebral compressive myelopathy in horses
por: Donnelly, Callum G., et al.
Publicado: (2023)

Chronic experimental autoimmune encephalomyelitis is an excellent model to study neuroaxonal degeneration in multiple sclerosis
por: Voskuhl, Rhonda R., et al.
Publicado: (2022)

Identification of Biomarkers in Cerebrospinal Fluid and Serum of Multiple Sclerosis Patients by Immunoproteomics Approach
por: Colomba, Paolo, et al.
Publicado: (2014)

Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers
por: Khademi, Mohsen, et al.
Publicado: (2013)

Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson’s Disease
por: Zimmermann, Milan, et al.
Publicado: (2022)

Development of robust targeted proteomics assays for cerebrospinal fluid biomarkers in multiple sclerosis
por: Guldbrandsen, Astrid, et al.
Publicado: (2020)

Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis
por: Schafflick, David, et al.
Publicado: (2020)

Cerebrospinal fluid–related tissue damage in multiple sclerosis patients with iron rim lesions
por: Wittayer, Matthias, et al.
Publicado: (2023)

Cerebrospinal Fluid Chitinases as Biomarkers for Amyotrophic Lateral Sclerosis
por: Costa, Júlia, et al.
Publicado: (2021)

Biomarkers in cerebrospinal fluid for amyotrophic lateral sclerosis phenotypes
por: Zhou, Jinxia, et al.
Publicado: (2023)

Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review
por: Davy, Vincent, et al.
Publicado: (2021)

Cerebrospinal fluid lipidomic biomarker signatures of demyelination for multiple sclerosis and Guillain–Barré syndrome
por: Péter, Mária, et al.
Publicado: (2020)

Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis
por: Robinson, Tilman, et al.
Publicado: (2020)

Comparative Analysis of Neurodegeneration and Axonal Dysfunction Biomarkers in the Cerebrospinal Fluid of Patients with Multiple Sclerosis
por: Kulczyńska-Przybik, Agnieszka, et al.
Publicado: (2022)

Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis
por: Ioannides, Zara A, et al.
Publicado: (2021)

Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?
por: Abdelhak, Ahmed, et al.
Publicado: (2015)

Effects of Repeated Intrathecal Triamcinolone-Acetonide Application on Cerebrospinal Fluid Biomarkers of Axonal Damage and Glial Activity in Multiple Sclerosis Patients
por: Rommer, P. S., et al.
Publicado: (2014)

Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2019)

Cerebrospinal Fluid and Blood Cytokines as Biomarkers for Multiple Sclerosis: A Systematic Review and Meta-Analysis of 226 Studies With 13,526 Multiple Sclerosis Patients
por: Bai, Zhile, et al.
Publicado: (2019)

Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis
por: Petrou, Panayiota, et al.
Publicado: (2022)

Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosis
por: Ehling, Rainer, et al.
Publicado: (2011)

Cerebrospinal fluid GAP-43 in early multiple sclerosis
por: Rot, U, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8edlrbs61ccoq3paibhi3r5bpj